Trials / Completed
CompletedNCT00161746
Safety and Immunogenicity Study of 3 Vaccinations With TICOVAC in 2 Dosages in Healthy Children Aged Between 6 Months and 3 Years
Multicentre Randomized Double-Blind Phase II/III Study on the Safety and Immunogenicity of Three Vaccinations With TICOVAC in Two Dosages in Healthy Children Aged Between Six Months and Three Years
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 6 Months – 47 Months
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate a) whether the seroconversion rates in children are equivalent after two and/or three partial vaccinations with TICOVAC 0.25 mL and TICOVAC 0.5 mL, and b) whether there is a difference in terms of safety between the two products.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Tick-Borne Encephalitis (TBE) Vaccine (Inactivated) |
Timeline
- Start date
- 1998-04-01
- Completion
- 1999-06-01
- First posted
- 2005-09-13
- Last updated
- 2015-05-21
Locations
7 sites across 1 country: Austria
Source: ClinicalTrials.gov record NCT00161746. Inclusion in this directory is not an endorsement.